Niagen Bioscience (NAGE) Asset Writedowns and Impairment (2016 - 2026)
Niagen Bioscience's (NAGE) quarterly Asset Writedowns and Impairment came in at $85000.0 in Q1 2026, up 106.43% year-on-year from $41175.3 in Q1 2025, and up 214.81% on a QoQ basis from $27000.0 in Q4 2025.
Niagen Bioscience (NAGE) Asset Writedowns and Impairment (2016 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 11 years of Asset Writedowns and Impairment data on file, last reported at $85000.0 in Q1 2026.
- On a quarterly basis, Asset Writedowns and Impairment rose 106.43% year-over-year to $85000.0 in Q1 2026; TTM through Mar 2026 was $189000.0, a 107.24% increase from a year earlier, with the FY2025 full-year figure at -$1.2 million, up 3.03% from the prior year.
- Asset Writedowns and Impairment for Q1 2026 stood at $85000.0, up from $27000.0 in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for NAGE reached as high as $400000.0 in Q2 2023 and fell as low as -$1.3 million in Q1 2025.
- Historically, Asset Writedowns and Impairment has averaged -$141941.2 across 5 years, with a median of $12000.0 in 2024.
- Across the five-year window, Asset Writedowns and Impairment jumped 8100.0% in 2023 and slumped 3874.29% in 2025, its largest moves.
- Year by year, Asset Writedowns and Impairment stood at -$28000.0 in 2022, then tumbled by 3264.29% to -$942000.0 in 2023, then sank by 39.49% to -$1.3 million in 2024, then soared by 102.05% to $27000.0 in 2025, then soared by 214.81% to $85000.0 in 2026.
- Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $85000.0 in Q1 2026, $27000.0 in Q4 2025, and -$12000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Niagen Bioscience | 258.53 Mn | 191.98 Mn | 19.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 85,000.00 |
| Mar 31, 2026 | 85,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Sep 30, 2025 | -12,000.00 |
| Sep 30, 2025 | -12,000.00 |
| Jun 30, 2025 | 89,000.00 |
| Jun 30, 2025 | 89,000.00 |
| Mar 31, 2025 | -1.32 Mn |
| Mar 31, 2025 | -1.32 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Sep 30, 2024 | 12,000.00 |
| Sep 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 35,000.00 |
| Mar 31, 2024 | 35,000.00 |
| Dec 31, 2023 | -942,000.00 |
| Dec 31, 2023 | -942,000.00 |